Sputnik V Vaccine's Efficacy Against Omicron-Caused Hospitalization Confirmed
The Gamaleya National Research Center of Epidemiology and Microbiology recently announced that Vaccines, the leading peer-reviewed medical journal, had published the results of a joint study showing the two-dose Sputnik V vaccine is 97% effective against hospitalization caused by the Omicron variant of coronavirus (B.1.1.529) among those vaccinated with 3 or 4 components (re-vaccination with Sputnik Light or Sputnik V after Sputnik V).
The study was conducted from January 11 to February 21, 2022, involving over 1,000 patients in Moscow.
The article was published on June 13, 2022.
As the study authors noted, '... vaccination with Sputnik V and Sputnik Light has high effectiveness for protection against hospitalization.'
'The reduction in the severity of COVID-19 regarding the Omicron variant was also observed.'
To date, Sputnik V has been authorized in 71 countries with a total population of over 4 billion people, and Sputnik Light has been approved in more than 30 countries.
Sputnik Light is a universal booster to other COVID-19 vaccines optimally configured on the adenoviral platform.
Note: This announcement was curated for mobile readership.